Pilot study to evaluate the potential of growing out tumor infiltrating lymphocytes from cervical carcinoma

Pilot study to evaluate the potential of growing out tumor infiltrating lymphocytes from cervical carcinoma - TIL study cervical carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53901

Enrollment

Registered

2023-02-23

Start date

2023-06-26

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Histologically proven cervical carcinoma of at least FIGO 2018 stage IB1 • Age above 18 years • Patients must have an indication for routine investigation or treatment under general anesthesia during which tumor material can be obtained • Able to provide written informed consent

Exclusion criteria

Exclusion criteria: • History of bleeding disorders

Design outcomes

Primary

Measure	Time frame
• To collect malignant (primary tumor or metastases) tissue from patients with cervical carcinoma. • To set up a TIL culture protocol for cervical carcinoma, resulting in a TIL product with sufficient cell numbers for adoptive T cell therapy • To evaluate potency of the TIL product through reactivity assays	—

Countries

Netherlands

Outcome results